Year in Review #ACR22 GLORIA Low steroid usage: lower DAS28, reduced joint damage BUT 24% increased adverse effects ⁦@RheumNow⁩ https://t.co/vYTAhoQEqr

Ab1012 #ACR22 @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS 21% PsA pts on opioids, 27% AS on opioids Opioid users - more co-morbidities, 🚬, worse disease Tended to higher use of anti-rheumatic drugs Higher health care utilizations, medical $$ @RheumNow

@RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendations BUT, this misses a HUGE opportunity to stress that inflammatory arthritis pts have higher risks and need greater emphasis on modifiable risk factors than gen pop #ACR22 @RheumNow

CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc

• Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Art…

Look at these graphs and try and tell me that sex and gender doesn't matter in RA. We have seen in study after study after study - sex and gender matters. ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN

• https://twitter.com/TheLancetRheum/status/1572873396123504641

New IgG4-RD therapeutic avenues, mechanistically driven (B cell-CTL interaction): inebilizumab: registered for NMO, ph3 now obexelimab: novel dual MOA ?safer, ph3 now rilzabrutinib: BTKi, ph2 now elotuzumab: targets SLAMF7, MM registered, NIH study John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS

Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H

One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations! #ACR22 @RheumNow https://t.co/dzHXeahsHT

• https://twitter.com/rheum_cat/status/1591849758859341824

Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe? Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so Much more to understand across tumor streams ABST0760 #ACR22 https://t.co/z1rhAJZ9gj

What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI Overall performance basically the same between all three. Important details in 🧵 but reasonable to say you can be happy with whatever you’ve got! ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38

To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui

Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate! Black pts 70% less likely to reach target compared to whites! #ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5

Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y

• Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of T…